Clinical biotechnology company: Aeglea BioTherapeutics, Inc. (AGLE)

Aeglea Biotherapeutics, Inc. (NASDAQ: AGLE) is a Delaware Corporation Aeglea BioTherapeutics Holdings, LLC, a limited liability company, was converted into a joint-stock company in March 2015. Headquartered in Austin, Texas, the United States, it has 61 full-time employees and is a clinical Biotechnology Company , designed and developed human enzyme therapy for the treatment of rare genetic diseases and cancer patients.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/agle.html

Aeglea Biotherapeutics (AGLE)

Aeglea Biotherapeutics is committed to developing enzyme based amino acid metabolic processes that change cancer and genetic diseases, so as to achieve the goal of cure. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/agle.html

The main candidate products of Aeglea Biotherapeutics include pegzilargenase, a recombinant human arginase 1 enzyme, which is in the early clinical development stage of arginase 1 deficiency, which is an autosomal recessive metabolic disease caused by a significant decrease in the activity of natural arginase 1 enzyme; And the treatment of arginine dependent cancer. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/agle.html

Aeglea Biotherapeutics pre clinical pipeline products include: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/agle.html

• AEB4104， A recombinant human enzyme that can degrade amino acid homocysteine and homocysteine in its oxidized form;
• AEB5100， A recombinant human enzyme that degrades plasma cystine and cysteine;
• AEB3103， An engineered human enzyme that targets the degradation of amino acid cysteine/cysteine;
• AEB2109， An engineered human enzyme that targets the degradation of amino acid methionine.

Aeglea BioTherapeutics and Merck Sign a clinical cooperation agreement to evaluate the combination of pegzilargenase and Merck's anti PD1 therapy pembrolizumab for the treatment of small cell lung cancer patients. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/agle.html

Aeglea Biotherapeutics (AGLE) Historical Encyclopedia

Aeglea on 6/16/2015 Submission of Prospectus to the SEC , launched on NASDAQ on April 7, 2016, issued 5 million shares at a price of $10, and planned to raise $50 million, stock code: AGLE. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/agle.html

On June 22, 2023, Aeglea BioTherapeutics (NASDAQ stock code: AGLE) is acquiring privately held Spyre Therapeutics. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/agle.html

Aeglea Biotherapeutics (AGLE) US equity investment

On November 27, 2023, Aeglea BioTherapeutics, Inc. (AGLE) announced to change its name to Spyre Therapeutics, Inc. 。 From the opening on November 28, 2023, Spyre will be traded on NASDAQ with the stock code of "SYRE". The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/agle.html